Xencor, Inc Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Xencor, Inc (XNCR) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $8.73 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-10
- Xencor, Inc net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $8.73M, a 9.66% decline year-over-year.
- Xencor, Inc net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$104.27M.
- Xencor, Inc net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$127.67M, a 1941.41% decline year-over-year.
- Xencor, Inc net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was $8.62M.
- Xencor, Inc net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$213.65M.
- Xencor, Inc net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$185.11M.
- Xencor, Inc net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$2.28M.
- Xencor, Inc net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$1.28M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | $8.73M 10-Q · filed 2017-05-10 | -$95.54M derived: sum of 2 quarters · filed 2017-05-10 | -$223.21M derived: sum of 3 quarters · filed 2017-05-10 | -$214.59M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-12-31 | -$104.27M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$231.94M derived: sum of 2 quarters · filed 2017-03-01 | -$223.31M derived: sum of 3 quarters · filed 2017-03-01 | -$213.65M 10-K · filed 2017-03-01 |
| 2016-09-30 | -$127.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | -$119.04M derived: sum of 2 quarters · filed 2016-11-02 | -$109.38M 10-Q · filed 2016-11-02 | -$151.07M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-06-30 | $8.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $18.28M 10-Q · filed 2016-08-03 | -$23.41M derived: sum of 3 quarters · filed 2017-05-10 | -$16.47M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-03-31 | $9.66M 10-Q · filed 2017-05-10 | -$32.03M derived: sum of 2 quarters · filed 2017-05-10 | -$25.10M derived: sum of 3 quarters · filed 2017-05-10 | -$126.39M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | -$41.69M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$34.76M derived: sum of 2 quarters · filed 2017-03-01 | -$136.05M derived: sum of 3 quarters · filed 2017-03-01 | -$185.11M 10-K · filed 2017-03-01 |
| 2015-09-30 | $6.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | -$94.36M derived: sum of 2 quarters · filed 2016-11-02 | -$143.42M 10-Q · filed 2016-11-02 | -$144.00M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$101.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | -$150.35M 10-Q · filed 2016-08-03 | -$150.94M derived: sum of 3 quarters · filed 2017-03-01 | -$151.51M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | -$49.06M 10-Q · filed 2016-05-02 | -$49.65M derived: sum of 2 quarters · filed 2017-03-01 | -$50.22M derived: sum of 3 quarters · filed 2017-03-01 | -$50.89M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$587.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$1.16M derived: sum of 2 quarters · filed 2017-03-01 | -$1.83M derived: sum of 3 quarters · filed 2017-03-01 | -$2.28M 10-K · filed 2017-03-01 |
| 2014-09-30 | -$573.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | -$1.25M derived: sum of 2 quarters · filed 2015-11-04 | -$1.70M 10-Q · filed 2015-11-04 | -$1.71M derived: sum of 4 quarters · filed 2016-03-08 |
| 2014-06-30 | -$675.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$1.12M 10-Q · filed 2015-08-05 | -$1.13M derived: sum of 3 quarters · filed 2016-03-08 | -$1.52M derived: sum of 4 quarters · filed 2016-03-08 |
| 2014-03-31 | -$448.00K 10-Q · filed 2015-05-05 | -$459.00K derived: sum of 2 quarters · filed 2016-03-08 | -$843.00K derived: sum of 3 quarters · filed 2016-03-08 | -$1.18M derived: sum of 4 quarters · filed 2016-03-08 |
| 2013-12-31 | -$11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | -$395.00K derived: sum of 2 quarters · filed 2016-03-08 | -$730.00K derived: sum of 3 quarters · filed 2016-03-08 | -$1.28M 10-K · filed 2016-03-08 |
| 2013-09-30 | -$384.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$719.00K derived: sum of 2 quarters · filed 2014-11-10 | -$1.27M 10-Q · filed 2014-11-10 | |
| 2013-06-30 | -$335.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-01 | -$883.00K 10-Q · filed 2014-08-01 | ||
| 2013-03-31 | -$548.00K 10-Q · filed 2014-05-15 | |||
| 2012-12-31 | -$1.16M 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |